Take charge of your finances with these top budget monitoring apps that make tracking spending simple, smart, and stress-free.
Updated
January 8, 2026 6:36 PM
.webp)
A phone next to a laptop, displaying a stock market app. PHOTO: UNSPLASH
Managing personal finances can feel overwhelming, especially with the countless expenses we juggle daily. Thankfully, budget monitoring apps are hereto save the day. These handy tools help you track your spending, set financial goals, and build better money habits—all from the convenience of your smartphone.
Whether you're saving for a vacation, paying off debt, or just trying to avoid those end-of-the-month surprises, budget tracker apps can provide clarity and control over your finances. Here are 5 budget monitoring apps that will keep your spending on track.
If simplicity is what you’re after, Monefy is the solution. Known for its highly intuitive interface, Monefy lets users track their spending with just a few taps. Unlike many budget apps that overwhelm you with features, Monefy focuses on the essentials, making it great for beginners or anyone looking for a straightforward way to manage their money.
Monefy is perfect for users who want a no-frills app to track spending or beginners just dipping their toes into budgeting.
Budgeting doesn’t have to feel like a chore, and Fortune City proves just that. This app gamifies your financial habits by turning expense tracking into a city-building game. Every category of spending contributes to your virtual city’s development, making it an enjoyable way to visualize where your money is going.
Fortune City is ideal for those who find traditional budgeting boring or intimidating and want a fun way to stay consistent.
Jupiter combines the best of both worlds: digital banking and budgeting. This app integrates directly with your bank account, automatically categorizing transactions and providing insights into your spending patterns. It’s not just a budget tracker—it’s a full-fledged financial assistant.
Jupiter is best for users who want a hands-off budgeting experience and prefer an all-in-one app for banking and money management.
Inspired by the envelope budgeting method, GoodBudget offers a digital twist on this classic approach. Instead of physical envelopes, you allocate your money into virtual "envelopes" for different spending categories. This app encourages disciplined spending and is particularly effective for budgeters who like to plan ahead.
GoodBudget is ideal for planners who like a structured approach to budgeting and don’t mind manual tracking.
Wally is a feature-packed app designed for users who want deep insights into their spending habits. Its sleek design, multi-currency support, and detailed financial reports make it a standout option, especially for frequent travelers or professionals juggling multiple accounts.
Wally is perfect for users who want advanced budgeting tools and detailed insights, especially those with international financial needs.
Budget monitoring apps are powerful tools that simplify the often-daunting task of managing your finances. Whether you’re drawn to the playful gamification of Fortune City, the structured approach of GoodBudget, or the all-in-one convenience of Jupiter, there’s an app tailored to your preferences and goals.
These apps don’t just track your spending—they help you build better habits, gain financial clarity, and take control of your money. With the right app in your pocket, managing your budget becomes less of a chore and more of are warding journey toward financial freedom. So why wait? Choose an app, start tracking, and watch your financial confidence grow!
Keep Reading
METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body
Updated
May 14, 2026 3:02 PM

HIV-1 virus particles, coloured red. PHOTO: UNSPLASH
Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.
The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.
Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.
The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.
That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.
METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.
The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.
One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.
Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.
METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.
The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.
Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."
The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.
For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.